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ABSTRACT
The development of sophisticated magnetic
resonance imaging techniques and software for medical
imaging processing and analysis has led to a significant
progress in multiple sclerosis research and clinical care. The
measurement of brain volumes provides a quantitative
representation of damage, thus facilitating the objective
follow-up process. The parameters obtained, though not
being used routinely in clinical practice, are more and more
often applied in clinical studies. The amount of whole brain
and regional atrophy, estimated from serial scans, is
considered important not only for disease progression, but
also for cognitive dysfunction which is common in multiple
sclerosis. In this paper we describe a volumetric study of
two magnetic resonance scans of a patient with relapsing-
remitting multiple sclerosis, performed 16 months one after
the other, and analyzed using FSL SIENA software. Analysis
demonstrated brain volume reduction of 1.7% between the
two scans. We discuss the advantages of the method and
its possible clinical applications.
Keywords: Brain Volume, Brain Atrophy, Magnetic
Resonance Imaging (MRI), Multiple Sclerosis
INTRODUCTION
The conceptions about the nature of multiple
sclerosis (MS) and the implicated pathological processes
have evolved significantly from the classical era of Charcot
to present day. The initial conception of an inflammatory
and demyelinating disease with exclusive damage to the
white brain matter has been replaced by more recent ones.
They not only consider the lesions of the gray matter, but
discuss their possible leading role for the irreversible
disability and cognitive impairment that develop in the
course of the disease [1].
Since the introduction of magnetic resonance imaging
(MRI) in research and in the diagnostic process and follow-
up of patients with MS, new techniques for quantitative
assessment have been sought. This would not have been
possible without the development of information technology
and the creation of powerful specialized software products.
The measurement of brain volume, white and gray matter,
and lesions, is able to provide a quantitative representation
of the impairment [2]. The pathological process can thus be
followed-up using serial measurements at specified time
intervals. Such option could be very important in terms of
assessing the efficacy of treatment. Though these
measurements are not currently used in routine clinical
practice, they play an important role in clinical trials of
potential new drugs [2, 3].
The pathological process in MS leads to the
formation of focal alterations of the central nervous system
which can be visualized on routine structural MRI [4].
However, if some areas of white and gray brain matter
appear normal on conventional magnetic resonance imaging,
they may also be affected by the pathological process. They
are described as “normal appearing white matter, NAWM”
and “normal-appearing grey matter, NAGM”, respectively.
These areas are subject to alterations which are “invisible”
through routine assessments, but are of great importance
for the development of brain atrophy in MS. The
quantitative measurement of general and regional brain
atrophy in MS is an essential addition to the assessment of
cognition which is becoming more and more important in
research and practice [5]. In fact, a certain degree of brain
atrophy, demonstrated as a reduction of brain volume by
computerized analysis of structural magnetic resonance
images, may be present in healthy persons. Giorgio et al.
have described a progressive decrease of gray matter volume
after middle age, as well as a decrease of white matter volume
beginning in younger adulthood [6]. But while in healthy
individuals the loss of brain volume reaches 0.3% per year,
in patients with MS it is between 0.6% and 1% [4]. Atrophy
begins early in the course of the disease. Its development
has even been described in patients with clinically isolated
syndrome, followed up for a one-year period, at the end of
which they have conformed to the diagnostic criteria for
multiple sclerosis [7].
Current methods used to assess whole-brain atrophy
in patients with MS can be classified into 2 groups based
on their reliance on segmentation and registration algorithms.
Segmentation-based methods employed to measure whole-
brain atrophy in MS include the brain parenchymal fraction,
the index of brain atrophy, the whole-brain ratio, the brain
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to intracranial capacity ratio, and SIENAX, among others.
Current registration-based methods used to measure whole-
brain atrophy in MS include the brain boundary shift
integral, SIENA, statistical parametric mapping, template-
driven segmentation, and voxel-based morphometry [8].
Methods for measuring brain atrophy can also be divided
into manual, semi-automatic and automatic, based on their
level of independence of human intervention during image
processing. Among the automatic methods which may prove
useful not only in research but in clinical practice is SIENA
[9], part of FSL [10]. FSL is a comprehensive library of
analysis tools for MRI, functional MRI, and diffusion tensor
imaging data, written mainly by members of the Analysis
Group, FMRIB, Oxford, UK. Most of its tools can be run
both from the command line and as “point-and-click”
graphical user interfaces. SIENA is the routine which
estimates percentage brain volume change (PBVC) between
two input images, taken of the same subject, at different
points in time. It calls a series of FSL programs to strip the
non-brain tissue from the two images, register the two brains
(under the constraint that the skulls are used to hold the
scaling constant during the registration) and analyse the
brain change between the two time points. It is also possible
to project the voxelwise atrophy measures into standard
space in a way that allows for multi-subject voxelwise
statistical testing [9, 10].
CASE REPORT
We describe a volumetric study of two 3D T1 MRI
scans of a patient with relapsing-remitting multiple sclerosis,
performed 16 months one after the other, and analyzed using
SIENA. The patient is a 34-year-old female, E.K. Her first
symptoms had appeared 2 years before the first
presentation to the clinic: numbness of the extremities, mild
weakness, and imbalance. Two relapses had been described
thus far. The initial clinical exam was normal. Neurological
exam showed mild paraparesis, hyperreflexia, bilateral
Babinski’s sign, mild locomotor and dynamic ataxia.
Expanded disability status scale (EDSS) score was 2.0. The
patient conformed to the clinical diagnostic criteria for
relapsing-remitting multiple sclerosis [11]. MRI was
performed, showing multiple subcortical white matter
lesions, hypointense on T1 and hyperintense on T2, in line
with the diagnosis of MS (Fig. 1A). The patient was
scheduled for clinical and MRI follow-up, and 16 months
later she presented to the clinic for a second time. No
relapses had been documented since the previous visit.
Clinical and neurological exams showed no dynamics. A
second MRI scan was performed (Fig. 1B). 3D T1 series from
both scans were processed through SIENA in order to
calculate the difference in brain volume between the two
time points. After processing by the different routines, a
final brain edge movement image was produced (Fig. 2) and
estimated PBVC was output. Results showed brain volume
reduction of 1.7% between the two MRI scans.
Fig. 1. T1 3D MRI scans: baseline (A) and after 16
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Fig. 2. Brain edge movement image (SIENA output)
DISCUSSION
For the purpose of calculating PBVC between 2 time
points in our patient with MS we used SIENA, a relatively
straightforward method. While currently applied in research
and clinical trials, such techniques constantly improve,
becoming easier and more reliable, and will most probably
be included soon in routine assessment procedures. In our
case we found brain volume reduction of 1.7% between the
two scans (16 months). This value is slightly higher than
what we expected according to published data [4]. Our
findings, though limited to a single case, are in line with the
conception of progressive brain tissue loss and
neurodegeneration in MS. We discuss possible bias due to
the lack of manual correction and to the slight discrepancy
between head positions on the two MRI scans. An
interesting fact is that despite the rather high PBVC, no new
clinical symptoms or increase of disability were noted in our
patient. This could be explained by the theory for
disagreement between clinical and neuroimaging findings in
MS, known as the “clinico-radiological paradox” [12],
though it is usually discussed in relation with the load of
demyelinating lesions rather than with atrophy. According
to some authors, unlike lesion based measures, volumetric
MRI assessment of brain atrophy shows a strong correlation
with functional outcome, and the presence of early atrophy
predicts a worse disease course [13]. Whether the brain
volume reduction in our patient will prove to be a marker of
further functional deterioration remains a question which will
be answered after follow-up. In any case, a single clinical
example is not sufficient for the purpose of establishing
dependencies, and larger cohorts are needed. An interesting
topic for investigation and discussion in such studies is the
correlation of PBVC with changes in cognitive functions.
Though at this stage automatic brain volume measurement
in a single clinical case as the one presented in this paper
may not be accurate for practical diagnostic or prognostic
purposes, this will undoubtedly change with the constant
development of technology and knowledge, and with the
increasing number of studies focusing on this exciting topic./ J of IMAB. 2013, vol. 19, issue 3 / http://www.journal-imab-bg.org 441
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